ProCE Banner Activity

WU-KONG1: Primary Analysis of a Phase II Study of Sunvozertinib in Patients With Previously Treated Advanced NSCLC and an EGFR Exon 20 Insertion Mutations

Conference Coverage

Primary analysis of part B of WU-KONG1 trial found that sunvozertinib had a manageable safety profile and durable efficacy in patients with NSCLC and EGFR exon20ins mutations who progressed on or after platinum-based chemotherapy.

Released: June 06, 2024

Expiration: June 05, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.